Roche has acquired a new hepatitis C therapy through its $230m (€168m) takeover of Anadys.
Under the merger – which saw Roche pay out $3.70 per share in an all-cash transaction – the Swiss pharma giant will receive Anadys’ lead ANA598 programme for the oral treatment of HepC.
It will also get the immunotherapy drug ANA773, which is currently in Phase I trials. Anadys, based in San-Diego, US, says the therapy could also have applications in other chronic infections as well as in oncology.
Jean-Jacques Garaud, global head of Roche Pharma research and early development, said: “This acquisition augments our already strong HCV portfolio.
“Our aim is to offer physicians and hepatitis patients a powerful combination of therapies that bring us closer to a cure, even without the use of interferon.
“Anadys’ compounds provide additional modes of action that could lead to interferon-free treatment regimens without viral resistance.”